Bromfenac sodium hydrate

• CAT Number: I000764
• CAS Number: 120638-55-3
• Molecular Formula: C15H12BrNO3 . 3/2 H2O . Na
• Molecular Weight: 383.17
• Purity: ≥95%
• Target: COX
• Solubility: DMSO ≥ 35 mg/mL
• Storage: Store at -20°C
• IUPAC Name: disodium;2-[2-amino-3-(4-bromobenzoyl)phenyl]acetate;trihydrate
• InChI: InChI=1S/2C15H12BrNO3.2Na.3H2O/c2*16-11-6-4-9(5-7-11)15(20)12-3-1-2-10(14(12)17)8-13(18)19;;;;;/h2*1-7H,8,17H2,(H,18,19);;;3*1H2/q;;2*+1;;;/p-2
• InChIKey: PPOSVVJOVKVBPW-UHFFFAOYSA-L
• SMILES: C1=CC(=C(C(=C1)C(=O)C2=CC=C(C=C2)Br)N)CC(=O)[O-].C1=CC(=C(C(=C1)C(=O)C2=CC=C(C=C2)Br)N)CC(=O)[O-].O.O.O.[Na+].[Na+]

Bromfenac sodium hydrate（Cat No.:I000764）, also known as Bromfenac monosodium salt sesquihydrate, is a potent and orally active inhibitor of cyclooxygenase (COX). It exhibits high selectivity for COX-1 and COX-2 with IC50 values of 5.56 and 7.45 nM, respectively. As a brominated nonsteroidal anti-inflammatory/analgesic drug (NSAID), Bromfenac sodium hydrate is commonly used in research studies focusing on postoperative inflammation and pain management following cataract surgery and pseudophakic cystic macular edema (CME). Its effectiveness in these contexts highlights its potential as a therapeutic option for ocular conditions associated with inflammation and edema.

Reference

[1]. Kirkman SK et al. Isolation and identification of bromfenac glucoside from rat bile. Drug Metab Dispos. 1998 Jul;26(7):720-3.
[2]. Abdullah TA et al. Chondroitin sulfate-chitosan nanoparticles for ocular delivery of bromfenac sodium: Improved permeation, retention, and penetration. Int J Pharm Investig. 2016 Apr-Jun;6(2):96-105.